Sep 2026
Abstract B013: Preclinical evaluation of NAMPT inhibitors with pyrimidine agonist antimetabolites floxuridine and 5-FU in rhabdomyosarcoma
While therapeutic advances have improved survival across pediatric malignancies, these gains have yet to be fully realized for patients with rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma. Our previous studies have shown that RMS is highly sensitive to targeting of nicotinamide phosphoribosyltr...
Jamie Gudyka, C. Yeung, Senna Munnikuysen et al.
· Cancer Research · 0 citations